Peptide medicines & new families.
Explore how defined peptide medicines work in specific clinical settings, from melanocortin signaling and amylin to GLP-2, local gut receptors and bone biology. Keep molecular identity, formulation, indications and measured outcomes together.
Guides in this topic
Peptide FundamentalsAbaloparatide vs Teriparatide: Bone Peptide Evidence
Abaloparatide and teriparatide are related to PTH-family biology and have product-specific osteoporosis evidence.
Updated 2026-10-29 ↗
Peptide FundamentalsAfamelanotide vs Melanotan II: Why the Difference Matters
Afamelanotide’s regulated implant record concerns pain-free light exposure in adults with erythropoietic protoporphyria.
Updated 2026-10-29 ↗
Peptide FundamentalsBivalirudin: A Peptide Targeting Thrombin During PCI
Bivalirudin is a peptide anticoagulant that directly inhibits thrombin. Its percutaneous-coronary-intervention evidence concerns a clinical strategy with specified comparators, accompanying medicines and event definitions.
Updated 2026-10-29 ↗
Peptide FundamentalsDesmopressin vs Vasopressin: Water Balance Is Not Blood Pressure
Desmopressin and vasopressin are related peptides, but their clinical questions are not interchangeable.
Updated 2026-10-29 ↗
Peptide FundamentalsDifelikefalin: A Peptide for a Specific CKD-Associated Itch Question
Difelikefalin addresses a specific itch question in adults receiving hemodialysis, rather than chronic kidney disease as a whole.
Updated 2026-10-29 ↗
Peptide FundamentalsEnfuvirtide: A Peptide That Targets HIV Fusion
Enfuvirtide is a peptide antiretroviral that targets a stage of HIV-1 entry: fusion of viral and cellular membranes.
Updated 2026-10-29 ↗
Peptide FundamentalsEptifibatide vs Tirofiban: Same Platelet Target, Different Molecules
Eptifibatide and tirofiban act at platelet glycoprotein IIb/IIIa, yet their structures are different: eptifibatide is a cyclic peptide and tirofiban is a nonpeptide antagonist.
Updated 2026-10-29 ↗
Peptide FundamentalsExenatide and Exendin-4: A Different GLP-1 Peptide Design
Exenatide is related to exendin-4 and acts at the GLP-1 receptor, but the product’s formulation remains central to its evidence.
Updated 2026-10-29 ↗
Peptide FundamentalsGlucagon: Why Rescue Medicine and Metabolic Coagonism Differ
Glucagon rescue medicines and glucagon-containing metabolic coagonists use a related biological pathway to answer different clinical questions.
Updated 2026-10-29 ↗
Peptide FundamentalsIcatibant: Why Bradykinin-Mediated Angioedema Is a Different Target
Icatibant targets the bradykinin B2 receptor. That mechanism is why its hereditary-angioedema evidence should be read separately from familiar allergy narratives centered on histamine.
Updated 2026-10-29 ↗
Peptide FundamentalsInsulin Analogues: How Sequence and Formulation Change the Profile
Insulin analogues show why small sequence changes and formulation choices can alter a peptide medicine’s time profile.
Updated 2026-10-29 ↗
Peptide FundamentalsLinaclotide vs Plecanatide: Peptides Acting in the Gut
Linaclotide and plecanatide are peptide GC-C agonists with product-specific gastrointestinal indications.
Updated 2026-10-29 ↗